belantamab

1. Background study

In both relapsed and refractory categories, patients with multiple myeloma (MM), a blood malignancy, do not show any improvement or at least a minor response after sixty days of starting treatment [1]. With an occurrence of 4.5 to 6 per 100,000 yearly, MM accounts for 1.8% of all new cancer cases and 2.1% of all cancer-related deaths in the United States each year [2]. MM presently has 160,000...